Screener / SEC EDGAR /CIK 0000730272 /10-K filed Feb 26, 2026, compared with Mar 14, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Biotechnology

Repligen Corp RGEN

Compare with peers Embed
Cash returned and share count

No buyback or stock pay figures in its 10-K data yet

XBRL, 10-K

New shares against shares bought back

Dilution: new shares, stock pay and buybacks · S-3 and 424B, 3 years; 10-K

Shares offered

Since Nov 17, 2023: 1 registration of shares for a merger, units or notes.

“424B3 d127719d424b3.htm Filed pursuant to Rule 424(b)(3) Registration No. 333-298546 MERGER PROPOSAL—YOUR VOTE IS VERY IMPORTANT Dear BioLife Solutions, Inc. Stockholder: On July 21, 2026, BioLife Solutions, Inc., a Delaware corporation (“BioLife” or the “Company”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) by and among, BioLife, Repligen Corporation, a Delaware corporation …”

424B3, Sep 4, 2026
Every offering filing

Paid in stock and bought back

No stock pay or buyback lines in the 10-K XBRL.

Where the cash came from and where it went

FY2025, from the cash flow statement in the 10-K, added up

Operating cash flowShares soldCash on hand usedCapital spendingAcquisitionsOther, net Operating cash flow: $117.4M Operating cash flow $117.4M Shares sold: $3.2M Shares sold $3.2M Cash on hand used: $191.3M Cash on hand used $191.3M Capital spending: $23.5M Capital spending $23.5M Acquisitions: $70.3M Acquisitions $70.3M Other, net: $218.1M Other, net $218.1M

Each number is a line of the cash flow statement as the company tagged it. "Other, net" is what those lines do not cover (investments bought and sold, other financing and investing lines, and exchange rates); Tickdelta does not estimate it.

Where the operating cash went, year by year

FY2016 to FY2025 · cash flow statements, 10-K XBRL

10 years
Operating cash, added up $885.4M 10 fiscal years, FY2016 to FY2025
Reinvested 144% capital spending and acquisitions, as a share of that cash
Returned to owners 2% buybacks and dividends, as a share of that cash
Debt repaid - gross repayments added up; debt that was refinanced counts each time
Fiscal yearOperating cashCapital spendingAcquisitionsBuybacks
Dec 31, 2025 $117.4M $23.5M$70.3M-
Dec 31, 2024 $175.4M $25.7M$54.8M-
Dec 31, 2023 $113.9M $36.2M$186.6M$14.4M
Dec 31, 2022 $172.1M $84.8M--
Dec 31, 2021 $119.0M $67.1M$149.9M-
Dec 31, 2020 $62.6M $22.5M$175.0M-
Dec 31, 2019 $67.2M $18.5M$182.2M-
Dec 31, 2018 $32.8M $10.6M--
Dec 31, 2017 $17.5M $5.5M$112.8M-
Dec 31, 2016 $7.5M $4.3M$44.6M-
Added up$885.4M $298.7M
34% of operating cash
$976.2M
110% of operating cash
$14.4M
2% of operating cash

Each bar is one fiscal year; its colours add up to what the cash flow statement says the company spent on each line, and the line across it is that year's operating cash flow. Spending above the line was paid from new debt, shares sold or cash on hand. A bar part links to the 10-K it comes from. A line the company did not report is left out, not estimated, so the shares are of operating cash only and can add up to more or less than 100%. Debt repaid is the gross amount, so refinanced debt is counted each time it is repaid. A reading aid, not a grade: Tickdelta does not say whether a split was good. Banks and insurers are left out.

Buybacks, dividends and share count

Year by year · XBRL, each 10-K

No buyback or share count data in the 10-K XBRL.

What the 10-Ks show for each CEO's years

Each CEO's years · the CEO of each fiscal year as named in the proxy's pay versus performance table

Mr. Loeillot

FY2024 to FY2025 · 2 years in the table
Operating cash flow
$292.8M
Capital spending
$49.2M
Acquisitions
$125.1M
Buybacks
$0
Stock-based pay
$80.7M
Diluted shares since FY2023
+0.3%
Revenue since FY2023
+17%
CEO pay (reported)
$33.6M
The proxy that names the CEO

Mr. Hunt

FY2021 to FY2023 · 3 years in the table
Operating cash flow
$405.0M
Capital spending
$188.1M
Acquisitions
$336.5M
Buybacks
$14.4M
Stock-based pay
$80.4M
Diluted shares since FY2020
+4.6%
Revenue since FY2020
+73%
CEO pay (reported)
$43.7M
The proxy that names the CEO

Sources

The cash flow statement, dividends per share and diluted share count in each 10-K's XBRL; Part II Item 2 of each 10-Q for monthly buybacks; offering prospectuses (S-3, 424B) for new shares; Form D data sets for private raises.

Also

CEO pay: what the CEO was paid over the same years.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/RGEN/export.csv") into a cell.

Next:CEO pay
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.